Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 18; p. 2802
• Main Authors: Miao, Ya-Ru, Liu, Chun-Jie, Hu, Hui, Yang, Mei, Guo, An-Yuan
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2022; MDPI
• Subjects: Biomarkers; Datasets; DNA repair; Gene expression; Genomes; Health aspects; Immune checkpoint; Immunotherapy; Lung cancer; Melanoma; Mutation; Mutation (Biology); Patients; PD-1 protein; Peg3 protein; Risk factors; SERPINB3; TMB; Tumors; China
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11182802

Although immune checkpoint blockade (ICB) therapies have achieved great progress, the patient response varies among cancers. In this study, we analyzed the potential genomic indicators contributing to ICB therapy response. The results showed that high tumor mutation burden (TMB) failed to predict response in anti-PD1 treated melanoma. SERPINB3 was the most significant response-related gene in melanoma and mutations in either SERPINB3 or PEG3 can serve as an independent risk factor in melanoma. Some recurrent mutations in CSMD3 were only in responders or non-responders, indicating their diverse impacts on patient response. Enrichment scores (ES) of gene mutations in 12 biological pathways were significantly higher in responders or non-responders. Next, the P-TMB calculated from genes in these pathways was significantly related to patient response with prediction AUC 0.74–0.82 in all collected datasets. In conclusion, our work provides new insights into the application of TMB in predicting patient response, which will benefit to immunotherapy research.